Quarterly Result20 Jan 2026, 02:12 pm
Senores Pharmaceuticals Reports Robust Q3 & 9M FY26 Financial Results with 164% & 165% Y-o-Y Growth in EBITDA Respectively
AI Summary
Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, announced its un-audited Financial Results for the 3rd Quarter and nine-months year ended 31st December 2025. The company reported a significant increase in income, EBITDA, and profit after tax for both Q3FY26 and 9MFY26. The operational highlights include strong cash flow from operations, approved ANDAs, and highest-ever revenue and EBITDA in Emerging Markets business. The company also provided an update on the acquisition of Apnar Pharmaceuticals.
Key Highlights
- Q3FY26 Consolidated Financial Highlights: Income - Rs. 175 Crs., EBITDA - Rs. 54 Crs., Profit After Tax - Rs. 34 Crs., a 164% a 186% a 105% Y-o-Y growth respectively.
- 9MFY26 Consolidated Financial Highlights: Income - Rs. 474 Crs., EBITDA - Rs. 138 Crs., Profit After Tax - Rs. 85 Crs., a 165% and 187% Y-o-Y growth respectively.
- Cash Flow from Operations for Q3FY26 stood at ~Rs. 19 crs & for 9MFY26 it stood at ~Rs. 51 crs.
- Highest-ever Revenue and EBITDA in Emerging Markets business in Q3FY26.
- Update on Acquisition of Apnar Pharmaceuticals — Phase 1 - 75% stake acquisition completed; Phase 2 - Balance 25% to be completed by Q2FY27.